GT719 Injection for the Treatment of Recurrent/Refractory CD19 Positive Adult B-cell Malignancies

This study is a prospective single-arm open-labled phase I/II clinical trial, including dose escalation and expansion phase, aims to evaluate the safety, efficacy, and cellular pharmacokinetics of GT719 Injection in relapsed/refractory CD19 positive adult B-cell non Hodgkin lymphoma (B-NHL) and B-acute lymphoblastic leukemia (B-ALL) patients. A total of 46 subjects (anticipated) will be enrolled in this study.

Trial Details

NCT ID
NCT06948981
Phase
PHASE1 / PHASE2
Sponsor
Grit Biotechnology
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • GT719 Injection
Locations (sample)
  • Tianjin, Tianjin Municipality, China|39.14222,117.17667

Key Eligibility Criteria

  • Voluntarily enrolled in the study, signed an informed consent form, and willing and able to comply with the study protocol.
  • Eastern Collaborative Oncology Group (ECOG) physical fitness status score of 0 or 1.
  • CD19 positivity confirmed by flow cytometry and/or histopathology.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →